Peptide Comparison
CagriSema vs Orforglipron
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Orforglipron has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: gi effects. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| CagriSema | Orforglipron | |
|---|---|---|
| Class | Amylin + GLP-1 combination | Oral non-peptide GLP-1 agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Dual amylin + GLP-1 receptor agonism | Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14] |
| Route | SC injection | Oral |
| Half-life | ~7 days | ~29-49 hrs |
| Dosage (research) | 2.4 mg / 2.4 mg SC weekly | 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15] |
| Evidence tier | Phase 3 | FDA-Approved |
| Research depth | 113 indexed | 197 indexed |
| Availability | Investigational | Prescription |
| Reported risks | GI effects; Phase 3 REDEFINE mixed results | GI effects; hepatic enzyme elevations |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick CagriSema or Orforglipron?
Orforglipron has stronger documented evidence (FDA-Approved) than CagriSema (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Orforglipron is the safer pick. CagriSema may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between CagriSema and Orforglipron?
CagriSema is classed as Amylin + GLP-1 combination; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: CagriSema, ~7 days; Orforglipron, ~29-49 hrs. Routes in published studies: CagriSema, SC injection; Orforglipron, Oral.
Which has stronger evidence, CagriSema or Orforglipron?
Orforglipron has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.
Which is more accessible, CagriSema or Orforglipron?
Orforglipron is FDA-approved and CagriSema is not. Catalog status: CagriSema, Investigational; Orforglipron, Prescription.
Are CagriSema and Orforglipron ever combined?
CagriSema and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…